Heng D.Y.C., Wells J.C., Rini B.I., Beuselinck B., Lee J.-L., Knox J.J., Bjarnason G.A., Pal S.K., Kollmannsberger C.K., Yuasa T., Srinivas S., Donskov F., Bamias A., Wood L.A., Ernst D.S., Agarwal N., Vaishampayan U.N., Rha S.Y., Kim J.J., Choueiri T.K.
European Urology 2014
Background: The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era of targeted therapy. Objective: To determine OS benefit of CN compared with no CN in mRCC patients treated with targeted therapies. Design, setting, and participants: Retrospective data from patients with synchronous mRCC (n = 1658) from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) were used to compare 982 mRCC patients who had a CN with 676 mRCC patients who did not. Outcome measurements and statistical analysis: OS was compared and hazard ratios (HRs) adjusted forIMDC poor prognostic criteria… (vermás)